Evidence record · ER-SEMAX-STROKE-020
Does Semax improve recovery after ischaemic stroke?
Semax improves cognitive or functional recovery after ischaemic stroke
Semax has limited regional human reports after ischaemic stroke, but the evidence is not strong enough for a dependable treatment conclusion. Small samples, unclear methods and limited independent replication prevent a reliable estimate of functional or cognitive benefit. The findings do not support replacing established urgent stroke care.
Claim boundary
What this verdict covers
The claim concerns patient-important neurological or cognitive recovery after diagnosed ischaemic stroke, alongside current care. Biomarker changes and non-randomised observations are insufficient on their own.
- Compound
- Semax
- Population
- People receiving care after ischaemic stroke
- Outcome
- Neurological function or cognition
- Record ID
- ER-SEMAX-STROKE-020
Evidence synthesis
What the research can support
Regional clinical reports describe neurological, cognitive or biological changes after Semax in stroke populations. Reporting and replication are too limited to establish a modern, generalisable treatment effect or comparative benefit.
Why the confidence is low
Stroke subtype, timing, co-treatment, allocation, blinding and outcome reporting are not consistently strong enough for a high-certainty estimate.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-SEMAX-STROKE-020 addresses one bounded question: Does Semax improve recovery after ischaemic stroke?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Insufficient and confidence is Low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Small Semax study in acute ischaemic stroke | The report describes outcomes in 30 people with acute hemispheric ischaemic stroke. | Its small size and reporting do not establish a dependable treatment effect. | 10 August 2026 |
| Semax neurological study | The study supplies additional regional human evidence. | It does not provide broad independent replication. | 10 August 2026 |
| FDA Semax compounding review | FDA assessed the evidence, product questions and safety gaps. | It does not replace an effectiveness trial or UK decision. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Semax for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Regional clinical reports describe neurological, cognitive or biological changes after Semax in stroke populations. Reporting and replication are too limited to establish a modern, generalisable treatment effect or comparative benefit. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Semax authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A prospectively registered multicentre randomised trial with concealed allocation, credible blinding, current-care comparator and validated functional outcomes. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation